The article examines the use of adipocyte fatty-acid-binding protein (Ap2) in treating metabolic syndrome disease. A small molecule BMS309403, an orally active, potent and selective inhibitor of Ap2, to inhibit the binding of endogenous fatty acids. Key information about the use of Ap2 inhibition is treating atheroscleorosis is also presented.